source
- Argenx's Vyvgart fails to beat placebo in Phase 3 Sjögren's disease trialArgenx announced that its marketed antibody therapy Vyvgart did not show superiority over placebo in a Phase 3 study involving patients with Sjögren's disease, a chronic autoimmune condition. The…
- Newron reports five deaths in schizophrenia trial as FDA keeps hold on evenamide studyNewron Pharmaceuticals disclosed that five participants have died in its late-stage schizophrenia trial, with four deaths among those receiving the investigational drug evenamide and one death amon…